Skip to main content

Table 1 Intratumoral PD-L2 expression and TILs in relation to clinicopathologic characteristics of PDAC

From: A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma

Intratumoral expression
   PD-L2 CD3 CD8 FOXP3
  N Low (0–1) High (2–3) P Low High P Low High P Low High P
Sex
 Male 158 125 33 0.540 113 45 0.805 129 29 0.066 131 27 0.502
 Female 147 112 35   107 40   131 16   126 21  
Age
< 60 106 86 20 0.340 76 30 0.138 86 20 0.139 88 18 0.663
≥60 199 152 47   144 55   174 25   169 30  
Location
 Head 181 136 45 0.348 130 51 0.913 153 28 0.885 147 34 0.030
 Body 62 49 13   44 18   53 9   59 3  
 Tail 62 52 10   46 16   54 8   51 11  
Grade
 Well 16 14 2 0.361 10 6 0.677 14 2 0.908 13 3 0.941
 Moderate 175 140 35   127 48   150 25   148 27  
 Low 114 85 29   83 31   96 18   96 18  
Tumor stage
 T1 51 43 8 0.494 33 18 0.252 40 11 0.212 45 6 0.694
 T2 176 135 41   133 43   149 27   147 29  
 T3 78 60 18   54 24   70 8   65 13  
Node stage
 N0 154 125 29 0.020 109 45 0.343 137 17 0.007 133 21 0.562
 N1 108 79 29   76 32   83 25   88 20  
 N2 43 40 3   35 8   35 8   36 7  
AJCC stage
 I 124 103 21 0.154 90 34 0.274 109 15 0.071 108 16 0.509
 II 138 101 37   95 43   111 27   113 25  
 III 43 34 9   35 8   40 3   36 7  
  1. TILs tumor infiltrating lymphocytes, PDAC pancreatic ductal adenocarcinoma